^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SMAD4 R361C

    i
    Other names: HSMAD4, Mothers Against DPP Homolog 4, SMAD, Mothers Against DPP Homolog 4, Deleted In Pancreatic Carcinoma Locus 4, SMAD, Mothers Against DPP Homolog 4, Mothers Against Decapentaplegic, Drosophila, Homolog Of, 4, MADH4, MAD, Mothers Against Decapentaplegic Homolog 4, Mothers Against Decapentaplegic Homolog 4, MAD Homolog 4, SMAD4, SMAD Family Member 4, Deletion Target In Pancreatic Carcinoma 4
    Entrez ID:
    4089
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    2years
    Enhanced Sensitivity to Detect Advanced Adenomaswith a Novel Blood-based CRC Test (AMP 2022)
    ColoScape™ Colorectal Cancer Detection Test is a novel highly-sensitive in vitro diagnostic assay using theqPCR-based multigene panel for the qualitative detection of colorectal cancer-associated gene mutations inliquid biopsy samples. The test targets 61 mutations in 8 genes and 7 methylation markers mostly associatedwith colorectal cancer utilizing our XNA technology which leverages a sequence-specific clamp made by xenonucleic acid (XNA) Target Genes: APC (1309 1367 1450) CTNNB1 (41 45) KRAS (12 13) BRAF 600 TP53 (R273HR175H R248Q) SMAD4 (R361C) PIK3CA (E545K) NRAS G12D Sensitivity for CRC: 88.9% 62.5% for Advancedadenoma Specificity 96%.
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    KRAS G12D • PIK3CA E545K • TP53 R175H • NRAS G12D • NRAS G12 • PIK3CA E545 • TP53 R248Q • SMAD4 R361C • TP53 R273H
    |
    ColoScape™ Colorectal Cancer Mutation Detection Test
    2years
    Enhanced Sensitivity to Detect Advanced Adenomas with a Novel Blood-based CRC Test (AMP 2022)
    ColoScape™ Colorectal Cancer Detection Test is a novel highly-sensitive in vitro diagnostic assay using the qPCR-based multigene panel for the qualitative detection of colorectal cancer-associated gene mutations in liquid biopsy samples. The test targets 61 mutations in 8 genes and 7 methylation markers mostly associated with colorectal cancer utilizing our XNA technology which leverages a sequence-specific clamp made by xeno- nucleic acid (XNA) Target Genes: APC (1309 1367 1450) CTNNB1 (41 45) KRAS (12 13) BRAF 600 TP53 (R273H R175H R248Q) SMAD4 (R361C) PIK3CA (E545K) NRAS G12D Sensitivity for CRC: 88.9% 62.5% for Advanced adenoma Specificity 96%.
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • SMAD4 (SMAD family member 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • APC (APC Regulator Of WNT Signaling Pathway)
    |
    KRAS G12D • PIK3CA E545K • TP53 R175H • NRAS G12D • NRAS G12 • PIK3CA E545 • TP53 R248Q • SMAD4 R361C • TP53 R273H
    |
    ColoScape™ Colorectal Cancer Mutation Detection Test
    almost3years
    Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib (ELCC 2022)
    P1, P2 | "ctDNA next-generation sequencing represents a promising technology but its optimal integration into testing NTRK gene fusions or resistance mutations still remains to be determined. Known resistance mutations in NTRK may cause progression, but further studies are warranted."
    Clinical • Circulating tumor DNA
    |
    FGFR2 (Fibroblast growth factor receptor 2) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ARID1A (AT-rich interaction domain 1A) • SMAD4 (SMAD family member 4) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    ARID1A mutation • FGFR2 mutation • FGFR2 fusion • ARID1A K1238fs + FGFR2 R210Q • NTRK1 F589L + NTRK1 G595R • NTRK1 G595R • SMAD4 R361C • NTRK fusion
    |
    Guardant360® CDx • GuardantOMNI
    |
    Vitrakvi (larotrectinib)